Regenerative Medicine Market Size, Share, Forecast, & Trends Analysis by Product (Gene Therapy, Stem Cell, Tissue Engineering) Application (Musculoskeletal, Cancer, Cardiovascular, Immunology, Dermatology, Ophthalmology) End User - Global Forecast to 2031
Regenerative Medicine Market Size, Share, Forecast, & Trends Analysis by Product (Gene Therapy, Stem Cell, Tissue Engineering) Application (Musculoskeletal, Cancer, Cardiovascular, Immunology, Dermatology, Ophthalmology) End User—Global Forecast to 2031
The global regenerative medicine market is projected to reach $37.27 billion by 2031 at a CAGR of 21.5% from 2024 to 2031.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities.
The growth of the global regenerative medicine market is driven by increasing approvals for new regenerative medicines, advancements in regenerative medicine, the rising incidence of chronic diseases, increasing funding for regenerative medicine development, and the growing applications of regenerative medicine in newer therapeutic areas. However, high treatment costs and ethical issues related to stem cells restrain the growth of this market.
Furthermore, the rising demand for personalized medicines, the increasing number of organ transplant procedures, and the strong product pipeline for regenerative medicines are expected to generate market growth opportunities. However, unfavorable reimbursement policies, complexities in the manufacture of regenerative medicines, and the lack of standardized frameworks for the safety & efficacy of regenerative medicines are major challenges in the global regenerative medicine market.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry in the last three to four years (2020–2024). The key players operating in the regenerative medicine market are Novartis AG (Switzerland), Biogen Inc. (U.S.), Kite Pharma, Inc. (U.S.), Spark Therapeutics, Inc. (U.S.), Integra LifeSciences Corporation (U.S.), Sarepta Therapeutics, Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Amgen Inc. (U.S.), CORESTEMCHEMON Inc. (South Korea), Smith & Nephew plc (England), Vertex Pharmaceuticals Incorporated (U.S.), CSL Behring, LLC (U.S.), Janssen Global Services, LLC (U.S.), Medtronic plc (Ireland), AbbVie Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Ferring Pharmaceuticals A/S (Sweden), Pfizer Inc. (U.S.), bluebird bio Inc. (U.S.), and Vericel Corporation (U.S.).
Among all the products studied in this report, the cell therapy segment is projected to register the highest CAGR of 25.0% during the forecast period. The cell therapy segment is further segmented into stem cell therapy, cell-based immunotherapy, and platelet-rich plasma therapy. Cell-based immunotherapy is projected to register the highest CAGR during the forecast period. The rapid growth of this segment is attributed to the increasing cancer prevalence, rising awareness regarding the use of CAR T-cell therapy, and rising number of approvals & clinical trials for cell-based immunotherapy. The funding for the development of cell-based immunotherapy is also increasing, further driving the market growth. For instance, in May 2024, German Cancer Aid provided a $2.8 million (Ђ2.6 million) grant to the Leibniz Institute for Immunotherapy (LIT) and University Hospital Regensburg (UKR) (Germany). The funding was earmarked for a clinical study focused on the use of stem-like CAR T-cells to treat patients with advanced lymphomas.
Among all the applications studied in this report, the oncology segment is projected to register the highest CAGR of 26.5% during the forecast period. Regenerative medicine offers various approaches, such as stem cell therapy, gene therapy, and tissue engineering, for treating cancer. These approaches provide personalized treatment options and help minimize the risk of side effects associated with traditional cancer treatments. Additionally, the rising funding for cancer treatment research contributes to the growth of this segment. For instance, in February 2024, BioNTech SE (Germany) invested USD 200 million in Autolus Therapeutics (U.K.) and established a strategic collaboration to support the cancer therapy pipeline.
Among all the end users studied in this report, the hospitals and clinics segment is projected to register the highest CAGR during the forecast period. Hospitals & clinics have developed infrastructure and highly skilled healthcare professionals, are easily accessible, and offer advanced treatments, including various therapies. Hence, patients are more inclined toward visiting hospitals & clinics. Many hospitals are also launching dedicated units for regenerative medicine, driving market growth. For instance, in April 2023, Jaslok Hospital (India) opened a Restorative and Regenerative Medicine Department aimed at treating complex diseases. This department offers orthobiologics for various cell-based treatments for bone and joint disorders, as well as platelet-rich plasma therapies for orthopedic, vascular, and cosmetic applications.
An in-depth analysis of the geographical scenario of the global regenerative medicine market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. Asia-Pacific is projected to register the highest CAGR of 25.0% during the forecast period. In 2024, Japan is expected to account for the largest share of the regenerative medicine market in Asia-Pacific. The large market share of Japan is attributed to the large population base aged 65 and older, government initiatives for the adoption of regenerative medicine, and supportive regulatory framework for the approval of regenerative medicine. For instance, Japan has implemented a conditional approval system for regenerative medicine, allowing companies to bring new therapies to market more quickly. The national healthcare system also covers these new therapies, providing further incentives for foreign companies to introduce their products in Japan.
Scope of the Report:
Regenerative Medicine Market Assessment—by Product
Regenerative Medicine Market Assessment—by End User
The global regenerative medicine market is projected to reach $37.27 billion by 2031 at a CAGR of 21.5% from 2024 to 2031.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities.
The growth of the global regenerative medicine market is driven by increasing approvals for new regenerative medicines, advancements in regenerative medicine, the rising incidence of chronic diseases, increasing funding for regenerative medicine development, and the growing applications of regenerative medicine in newer therapeutic areas. However, high treatment costs and ethical issues related to stem cells restrain the growth of this market.
Furthermore, the rising demand for personalized medicines, the increasing number of organ transplant procedures, and the strong product pipeline for regenerative medicines are expected to generate market growth opportunities. However, unfavorable reimbursement policies, complexities in the manufacture of regenerative medicines, and the lack of standardized frameworks for the safety & efficacy of regenerative medicines are major challenges in the global regenerative medicine market.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry in the last three to four years (2020–2024). The key players operating in the regenerative medicine market are Novartis AG (Switzerland), Biogen Inc. (U.S.), Kite Pharma, Inc. (U.S.), Spark Therapeutics, Inc. (U.S.), Integra LifeSciences Corporation (U.S.), Sarepta Therapeutics, Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Amgen Inc. (U.S.), CORESTEMCHEMON Inc. (South Korea), Smith & Nephew plc (England), Vertex Pharmaceuticals Incorporated (U.S.), CSL Behring, LLC (U.S.), Janssen Global Services, LLC (U.S.), Medtronic plc (Ireland), AbbVie Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Ferring Pharmaceuticals A/S (Sweden), Pfizer Inc. (U.S.), bluebird bio Inc. (U.S.), and Vericel Corporation (U.S.).
Among all the products studied in this report, the cell therapy segment is projected to register the highest CAGR of 25.0% during the forecast period. The cell therapy segment is further segmented into stem cell therapy, cell-based immunotherapy, and platelet-rich plasma therapy. Cell-based immunotherapy is projected to register the highest CAGR during the forecast period. The rapid growth of this segment is attributed to the increasing cancer prevalence, rising awareness regarding the use of CAR T-cell therapy, and rising number of approvals & clinical trials for cell-based immunotherapy. The funding for the development of cell-based immunotherapy is also increasing, further driving the market growth. For instance, in May 2024, German Cancer Aid provided a $2.8 million (Ђ2.6 million) grant to the Leibniz Institute for Immunotherapy (LIT) and University Hospital Regensburg (UKR) (Germany). The funding was earmarked for a clinical study focused on the use of stem-like CAR T-cells to treat patients with advanced lymphomas.
Among all the applications studied in this report, the oncology segment is projected to register the highest CAGR of 26.5% during the forecast period. Regenerative medicine offers various approaches, such as stem cell therapy, gene therapy, and tissue engineering, for treating cancer. These approaches provide personalized treatment options and help minimize the risk of side effects associated with traditional cancer treatments. Additionally, the rising funding for cancer treatment research contributes to the growth of this segment. For instance, in February 2024, BioNTech SE (Germany) invested USD 200 million in Autolus Therapeutics (U.K.) and established a strategic collaboration to support the cancer therapy pipeline.
Among all the end users studied in this report, the hospitals and clinics segment is projected to register the highest CAGR during the forecast period. Hospitals & clinics have developed infrastructure and highly skilled healthcare professionals, are easily accessible, and offer advanced treatments, including various therapies. Hence, patients are more inclined toward visiting hospitals & clinics. Many hospitals are also launching dedicated units for regenerative medicine, driving market growth. For instance, in April 2023, Jaslok Hospital (India) opened a Restorative and Regenerative Medicine Department aimed at treating complex diseases. This department offers orthobiologics for various cell-based treatments for bone and joint disorders, as well as platelet-rich plasma therapies for orthopedic, vascular, and cosmetic applications.
An in-depth analysis of the geographical scenario of the global regenerative medicine market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. Asia-Pacific is projected to register the highest CAGR of 25.0% during the forecast period. In 2024, Japan is expected to account for the largest share of the regenerative medicine market in Asia-Pacific. The large market share of Japan is attributed to the large population base aged 65 and older, government initiatives for the adoption of regenerative medicine, and supportive regulatory framework for the approval of regenerative medicine. For instance, Japan has implemented a conditional approval system for regenerative medicine, allowing companies to bring new therapies to market more quickly. The national healthcare system also covers these new therapies, providing further incentives for foreign companies to introduce their products in Japan.
Scope of the Report:
Regenerative Medicine Market Assessment—by Product
- Gene Therapy
- Cell Therapy
- Stem Cell Therapy
- Autologous Therapy
- Allogenic Therapy
- Platelet Rich Plasma Therapy
- Cell-based Immunotherapy
- Tissue Engineering
- Cardiology
- Ophthalmology
- Oncology
- Neurology
- Immunology & Inflammation
- Musculoskeletal
- Dermatology
- Other Applications
Regenerative Medicine Market Assessment—by End User
- Hospitals & Clinics
- Ambulatory Surgical Centers
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K
- Italy
- Spain
- Switzerland
- Netherlands
- Sweden
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
1. INTRODUCTION
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency and Limitations
1.4. Key Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.2. Data Collection and Validation Process
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews With Key Opinion Leaders from the Industry
2.3. Market Sizing & Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study
3. EXECUTIVE SUMMARY
4. MARKET INSIGHTS
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Drivers
4.2.1.1. Approvals for New Regenerative Medicines
4.2.1.2. Increasing Funding for Regenerative Medicine Development
4.2.1.3. Increasing Applications of Regenerative Medicine in Newer Therapy Areas
4.2.2. Restraints
4.2.2.1. Ethical Issues Related to Stem Cells
4.2.3. Opportunities
4.2.3.1. Rising Demand for Personalized Medicines
4.2.4. Challenges
4.2.4.1. Complexities in the Manufacture of Regenerative Medicines
4.2.5. Factor Analysis
4.3. Trends
4.3.1. Utilization of 3D Bioprinting in Regenerative Medicine
4.3.2. Integration of AI Tools in Regenerative Medicine Development
4.3.3. Induced Pluripotent Stem Cells
4.4. Regulatory Analysis
4.4.1. North America
4.4.1.1. U.S.
4.4.1.2. Canada
4.4.2. Asia-Pacific
4.4.2.1. Japan
4.4.2.2. China
4.4.2.3. India
4.4.3. Europe
4.4.4. Middle East & Africa
4.4.5. PRP Qualification Criteria
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of Substitutes
4.5.4. Threat of New Entrants
4.5.5. Degree of Competition
4.6. Investment and Funding Scenario
4.7. Pipeline Analysis
5. REGENERATIVE MEDICINE MARKET ASSESSMENT—BY PRODUCT
5.1. Overview
5.2. Cell Therapy
5.2.1. Cell-based Immunotherapy
5.2.2. Stem Cell Therapy
5.2.2.1. Allogenic Therapy
5.2.2.2. Autologous Therapy
5.2.3. Platelet-rich Plasma Therapy
5.3. Gene Therapy
5.4. Tissue Engineering Products
6. REGENERATIVE MEDICINE MARKET ASSESSMENT—BY APPLICATION
6.1. Overview
6.2. Musculoskeletal
6.3. Oncology
6.4. Ophthalmology
6.5. Immunology & Inflammation
6.6. Neurology
6.7. Dermatology
6.8. Cardiology
6.9. Other Applications
7. REGENERATIVE MEDICINE MARKET ASSESSMENT—BY END USER
7.1. Introduction
7.2. Hospitals & Clinics
7.3. Ambulatory Surgical Centers
8. REGENERATIVE MEDICINE MARKET ASSESSMENT—BY GEOGRAPHY
8.1. Overview
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.3. Europe
8.3.1. Germany
8.3.2. U.K.
8.3.3. France
8.3.4. Switzerland
8.3.5. Italy
8.3.6. Spain
8.3.7. Netherlands
8.3.8. Sweden
8.3.9. Rest of Europe
8.4. Asia-Pacific
8.4.1. Japan
8.4.2. China
8.4.3. Australia
8.4.4. India
8.4.5. South Korea
8.4.6. Rest of Asia-Pacific
8.5. Latin America
8.5.1. Brazil
8.5.2. Mexico
8.5.3. Rest of Latin America
8.6. Middle East & Africa
9. COMPETITION ANALYSIS
9.1. Overview
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
9.4. Competitive Dashboard
9.4.1. Industry Leaders
9.4.2. Market Differentiators
9.4.3. Vanguards
9.4.4. Emerging Companies
9.5. Market Share Analysis (2023)
9.5.1. Novartis AG (Switzerland)
9.5.2. Kite Pharma, Inc. (U.S.)
9.5.3. Biogen, Inc. (U.S.)
9.5.4. Bristol-Myers Squibb Company (U.S.)
9.5.5. Janssen Global Services, LLC (U.S.)
10. COMPANY PROFILES (BUSINESS OVERVIEW, FINANCIAL OVERVIEW, PRODUCT PORTFOLIO, STRATEGIC DEVELOPMENTS, SWOT ANALYSIS*)
10.1. Novartis AG
10.2. Kite Pharma, Inc. (A Subsidiary of Gilead Sciences, Inc.)
10.3. Janssen Global Services, LLC (A Subsidiary of Johnson & Johnson)
10.4. Bristol-Myers Squibb Company
10.5. Biogen Inc.
10.6. Smith & Nephew Plc
10.7. Amgen Inc.
10.8. Vericel Corporation
10.9. Integra Lifesciences Holdings Corporation
10.10. Pfizer Inc.
10.11. AbbVie Inc.
10.12. Sarepta Therapeutics, Inc.
10.13. Spark Therapeutics, Inc. (A Subsidiary of F. Hoffmann-La Roche Ag)
10.14. CORESTEMCHEMON, Inc.
10.15. CSL Behring, LLC (A Subsidiary of CSL Limited)
10.16. Takeda Pharmaceutical Company Limited
10.17. Ferring Pharmaceuticals
10.18. Medtronic plc
10.19. Bluebird Bio, Inc.
10.20. Vertex Pharmaceuticals Incorporated
(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)
11. APPENDIX
11.1. Available Customization
11.2. Related Reports
Table 1 U.S. FDA-Approved Cell & Gene Therapy Products (As of August 2024)
Table 2 Estimated Number of New Cancer Cases, by Region, 2022-2030 (Thousand)
Table 3 Comparison of Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation
Table 4 Risk Classification of Regenerative Medicines, by Type and Class
Table 5 Authorities/Organizations Funding and Investing In Regenerative Medicine-related Research & Development
Table 6 Regenerative Medicine Market: Pipeline Analysis
Table 7 Global Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 8 Estimated Number of New Leukemia Cases, by Region, 2022–2030 (Thousands)
Table 9 Global Regenerative Medicine Market for Cell Therapy, by Type, 2022–2031 (USD Million)
Table 10 Global Regenerative Medicine Market for Cell Therapy, by Country/Region, 2022–2031 (USD Million)
Table 11 Companies Offering Cell-Based Immunotherapy Solutions
Table 12 Global Regenerative Medicine Market for Cell-Based Immunotherapy, by Country/Region, 2022–2031 (USD Million)
Table 13 Companies Offering Stem Cell Therapy Solutions
Table 14 Characteristics Features of Stem Cell Therapy for Regenerative Medicine
Table 15 Global Stem Cell Therapy Market, by Type, 2022–2031 (USD Million)
Table 16 Global Regenerative Medicine Market for Stem Cell Therapy, by Country/Region, 2022–2031 (USD Million)
Table 17 Companies Offering Allogenic Therapy Solutions
Table 18 Global Regenerative Medicine Market for Allogenic Therapy, by Country/Region, 2022–2031 (USD Million)
Table 19 Companies Offering Autologous Cell Therapy
Table 20 Global Regenerative Medicine Market for Autologous Cell Therapy, by Country/Region, 2022–2031 (USD Million)
Table 21 Companies Offering Platelet-Rich Plasma (PRP) Therapy
Table 22 Global Regenerative Medicine for Platelet-Rich Plasma (PRP) Therapy, by Country/Region, 2022–2031 (USD Million)
Table 23 Companies Offering Gene Therapy Products
Table 24 Global Regenerative Medicine Market for Gene Therapy, by Country/Region, 2022–2031 (USD Million)
Table 25 Companies Offering Tissue Engineering Products
Table 26 Global Regenerative Medicine Market for Tissue Engineering Products, by Country/Region, 2022–2031 (USD Million)
Table 27 Global Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 28 Global Regenerative Medicine Market for Musculoskeletal Disorders, by Country/Region, 2022–2031 (USD Million)
Table 29 Global Regenerative Medicine Market for Oncology, by Country/Region, 2022–2031 (USD Million)
Table 30 Global Regenerative Medicine Market for Ophthalmology, by Country/Region, 2022–2031 (USD Million)
Table 31 Global Regenerative Medicine Market for Immunology & Inflammation, by Country/Region, 2022–2031 (USD Million)
Table 32 Global Regenerative Medicine Market for Neurology, by Country/Region, 2022–2031 (USD Million)
Table 33 Global Regenerative Medicine Market for Dermatology, by Country/Region, 2022–2031 (USD Million)
Table 34 Global Regenerative Medicine Market for Cardiology, by Country/Region, 2022–2031 (USD Million)
Table 35 Global Regenerative Medicine Market for Other Applications, by Country/Region, 2022–2031 (USD Million)
Table 36 Global Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 37 Global Regenerative Medicine Market for Hospitals & Clinics, by Country/Region, 2022-2031 (USD Million)
Table 38 Global Regenerative Medicine Market for Ambulatory Surgical Centers, by Country/Region, 2022-2031 (USD Million)
Table 39 Global Regenerative Medicine Market, by Country/Region, 2022–2031 (USD Million)
Table 40 North America: Regenerative Medicine Market, by Country, 2022–2031 (USD Million)
Table 41 North America: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 42 North America: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 43 North America: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 44 North America: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
Table 45 North America: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 46 U.S.: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 47 U.S.: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 48 U.S.: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 49 U.S.: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
Table 50 U.S.: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 51 Canada: Approved Regenerative Medicine, 2021-2024
Table 52 Canada: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 53 Canada: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 54 Canada: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 55 Canada: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 56 Canada: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 57 Europe: Regenerative Medicine Sector Data, Q2 2024 Vs. Q1 2023
Table 58 Europe: Regenerative Medicine Market, by Country/Region, 2022–2031 (USD Million)
Table 59 Europe: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 60 Europe: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 61 Europe: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 62 Europe: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
Table 63 Europe: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 64 Germany: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 65 Germany: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 66 Germany: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 67 Germany: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 68 Germany: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 69 U.K.: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 70 U.K.: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 71 U.K.: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 72 U.K.: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
Table 73 U.K.: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 74 France: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 75 France: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 76 France: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 77 France: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 78 France: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 79 Switzerland: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 80 Switzerland: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 81 Switzerland: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 82 Switzerland: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 83 Switzerland: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 84 Italy: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 85 Italy: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 86 Italy: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 87 Italy: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
Table 88 Italy: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 89 Spain: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 90 Spain: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 91 Spain: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 92 Spain: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 93 Spain: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 94 Netherlands: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 95 Netherlands: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 96 Netherlands: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 97 Netherlands: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 98 Netherlands: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 99 Sweden: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 100 Sweden: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 101 Sweden: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 102 Sweden: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 103 Sweden: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 104 Rest of Europe: Estimated Number of New Cancer Cases, by Country, 2022 Vs. 2030
Table 105 Rest of Europe: Recent Developments In The Regenerative Medicine Market
Table 106 Rest of Europe: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 107 Rest of Europe: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 108 Rest of Europe: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 109 Rest of Europe: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 110 Rest of Europe: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 111 Asia-Pacific: Regenerative Medicine Sector Data, Q2 2024 Vs. Q1 2023
Table 112 Asia-Pacific: Regenerative Medicine Market, by Country/Region, 2022–2031 (USD Million)
Table 113 Asia-Pacific: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 114 Asia-Pacific: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 115 Asia-Pacific: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 116 Asia-Pacific: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
Table 117 Asia-Pacific: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 118 Japan: Approved Regenerative Medicine
Table 119 Japan: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 120 Japan: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 121 Japan: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 122 Japan: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 123 Japan: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 124 China: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 125 China: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 126 China: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 127 China: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 128 China: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 129 Australia: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 130 Australia: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 131 Australia: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 132 Australia: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 133 Australia: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 134 India: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 135 India: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 136 India: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 137 India: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 138 India: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 139 South Korea: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 140 South Korea: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 141 South Korea: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 142 South Korea: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 143 South Korea: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 144 Rest of Asia-Pacific: Recent Developments in Regenerative Medicine Market, by Country
Table 145 Rest of Asia-Pacific: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 146 Rest of Asia-Pacific: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 147 Rest of Asia-Pacific: Stem Cell Therapy Market, by Type, 2022–2031 (USD Million)
Table 148 Rest of Asia-Pacific: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
Table 149 Rest of Asia-Pacific: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 150 Latin America: Regenerative Medicine Market, by Country/Region, 2022–2031 (USD Million)
Table 151 Latin America: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 152 Latin America: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 153 Latin America: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 154 Latin America: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
Table 155 Latin America: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 156 Brazil: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 157 Brazil: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 158 Brazil: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 159 Brazil: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 160 Brazil: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 161 Mexico: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 162 Mexico: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 163 Mexico: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 164 Mexico: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 165 Mexico: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 166 Rest of Latin America: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 167 Rest of Latin America: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 168 Rest of Latin America: Stem Cell Therapy Market, by Type, 2022–2031 (USD Million)
Table 169 Rest of Latin America: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 170 Rest of Latin America: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 171 Middle East & Africa: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 172 Middle East & Africa: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 173 Middle East & Africa: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 174 Middle East & Africa: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 175 Middle East & Africa: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 176 Recent Developments, by Company, 2021–2024
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency and Limitations
1.4. Key Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.2. Data Collection and Validation Process
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews With Key Opinion Leaders from the Industry
2.3. Market Sizing & Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study
3. EXECUTIVE SUMMARY
4. MARKET INSIGHTS
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Drivers
4.2.1.1. Approvals for New Regenerative Medicines
4.2.1.2. Increasing Funding for Regenerative Medicine Development
4.2.1.3. Increasing Applications of Regenerative Medicine in Newer Therapy Areas
4.2.2. Restraints
4.2.2.1. Ethical Issues Related to Stem Cells
4.2.3. Opportunities
4.2.3.1. Rising Demand for Personalized Medicines
4.2.4. Challenges
4.2.4.1. Complexities in the Manufacture of Regenerative Medicines
4.2.5. Factor Analysis
4.3. Trends
4.3.1. Utilization of 3D Bioprinting in Regenerative Medicine
4.3.2. Integration of AI Tools in Regenerative Medicine Development
4.3.3. Induced Pluripotent Stem Cells
4.4. Regulatory Analysis
4.4.1. North America
4.4.1.1. U.S.
4.4.1.2. Canada
4.4.2. Asia-Pacific
4.4.2.1. Japan
4.4.2.2. China
4.4.2.3. India
4.4.3. Europe
4.4.4. Middle East & Africa
4.4.5. PRP Qualification Criteria
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of Substitutes
4.5.4. Threat of New Entrants
4.5.5. Degree of Competition
4.6. Investment and Funding Scenario
4.7. Pipeline Analysis
5. REGENERATIVE MEDICINE MARKET ASSESSMENT—BY PRODUCT
5.1. Overview
5.2. Cell Therapy
5.2.1. Cell-based Immunotherapy
5.2.2. Stem Cell Therapy
5.2.2.1. Allogenic Therapy
5.2.2.2. Autologous Therapy
5.2.3. Platelet-rich Plasma Therapy
5.3. Gene Therapy
5.4. Tissue Engineering Products
6. REGENERATIVE MEDICINE MARKET ASSESSMENT—BY APPLICATION
6.1. Overview
6.2. Musculoskeletal
6.3. Oncology
6.4. Ophthalmology
6.5. Immunology & Inflammation
6.6. Neurology
6.7. Dermatology
6.8. Cardiology
6.9. Other Applications
7. REGENERATIVE MEDICINE MARKET ASSESSMENT—BY END USER
7.1. Introduction
7.2. Hospitals & Clinics
7.3. Ambulatory Surgical Centers
8. REGENERATIVE MEDICINE MARKET ASSESSMENT—BY GEOGRAPHY
8.1. Overview
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.3. Europe
8.3.1. Germany
8.3.2. U.K.
8.3.3. France
8.3.4. Switzerland
8.3.5. Italy
8.3.6. Spain
8.3.7. Netherlands
8.3.8. Sweden
8.3.9. Rest of Europe
8.4. Asia-Pacific
8.4.1. Japan
8.4.2. China
8.4.3. Australia
8.4.4. India
8.4.5. South Korea
8.4.6. Rest of Asia-Pacific
8.5. Latin America
8.5.1. Brazil
8.5.2. Mexico
8.5.3. Rest of Latin America
8.6. Middle East & Africa
9. COMPETITION ANALYSIS
9.1. Overview
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
9.4. Competitive Dashboard
9.4.1. Industry Leaders
9.4.2. Market Differentiators
9.4.3. Vanguards
9.4.4. Emerging Companies
9.5. Market Share Analysis (2023)
9.5.1. Novartis AG (Switzerland)
9.5.2. Kite Pharma, Inc. (U.S.)
9.5.3. Biogen, Inc. (U.S.)
9.5.4. Bristol-Myers Squibb Company (U.S.)
9.5.5. Janssen Global Services, LLC (U.S.)
10. COMPANY PROFILES (BUSINESS OVERVIEW, FINANCIAL OVERVIEW, PRODUCT PORTFOLIO, STRATEGIC DEVELOPMENTS, SWOT ANALYSIS*)
10.1. Novartis AG
10.2. Kite Pharma, Inc. (A Subsidiary of Gilead Sciences, Inc.)
10.3. Janssen Global Services, LLC (A Subsidiary of Johnson & Johnson)
10.4. Bristol-Myers Squibb Company
10.5. Biogen Inc.
10.6. Smith & Nephew Plc
10.7. Amgen Inc.
10.8. Vericel Corporation
10.9. Integra Lifesciences Holdings Corporation
10.10. Pfizer Inc.
10.11. AbbVie Inc.
10.12. Sarepta Therapeutics, Inc.
10.13. Spark Therapeutics, Inc. (A Subsidiary of F. Hoffmann-La Roche Ag)
10.14. CORESTEMCHEMON, Inc.
10.15. CSL Behring, LLC (A Subsidiary of CSL Limited)
10.16. Takeda Pharmaceutical Company Limited
10.17. Ferring Pharmaceuticals
10.18. Medtronic plc
10.19. Bluebird Bio, Inc.
10.20. Vertex Pharmaceuticals Incorporated
(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)
11. APPENDIX
11.1. Available Customization
11.2. Related Reports
Table 1 U.S. FDA-Approved Cell & Gene Therapy Products (As of August 2024)
Table 2 Estimated Number of New Cancer Cases, by Region, 2022-2030 (Thousand)
Table 3 Comparison of Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation
Table 4 Risk Classification of Regenerative Medicines, by Type and Class
Table 5 Authorities/Organizations Funding and Investing In Regenerative Medicine-related Research & Development
Table 6 Regenerative Medicine Market: Pipeline Analysis
Table 7 Global Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 8 Estimated Number of New Leukemia Cases, by Region, 2022–2030 (Thousands)
Table 9 Global Regenerative Medicine Market for Cell Therapy, by Type, 2022–2031 (USD Million)
Table 10 Global Regenerative Medicine Market for Cell Therapy, by Country/Region, 2022–2031 (USD Million)
Table 11 Companies Offering Cell-Based Immunotherapy Solutions
Table 12 Global Regenerative Medicine Market for Cell-Based Immunotherapy, by Country/Region, 2022–2031 (USD Million)
Table 13 Companies Offering Stem Cell Therapy Solutions
Table 14 Characteristics Features of Stem Cell Therapy for Regenerative Medicine
Table 15 Global Stem Cell Therapy Market, by Type, 2022–2031 (USD Million)
Table 16 Global Regenerative Medicine Market for Stem Cell Therapy, by Country/Region, 2022–2031 (USD Million)
Table 17 Companies Offering Allogenic Therapy Solutions
Table 18 Global Regenerative Medicine Market for Allogenic Therapy, by Country/Region, 2022–2031 (USD Million)
Table 19 Companies Offering Autologous Cell Therapy
Table 20 Global Regenerative Medicine Market for Autologous Cell Therapy, by Country/Region, 2022–2031 (USD Million)
Table 21 Companies Offering Platelet-Rich Plasma (PRP) Therapy
Table 22 Global Regenerative Medicine for Platelet-Rich Plasma (PRP) Therapy, by Country/Region, 2022–2031 (USD Million)
Table 23 Companies Offering Gene Therapy Products
Table 24 Global Regenerative Medicine Market for Gene Therapy, by Country/Region, 2022–2031 (USD Million)
Table 25 Companies Offering Tissue Engineering Products
Table 26 Global Regenerative Medicine Market for Tissue Engineering Products, by Country/Region, 2022–2031 (USD Million)
Table 27 Global Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 28 Global Regenerative Medicine Market for Musculoskeletal Disorders, by Country/Region, 2022–2031 (USD Million)
Table 29 Global Regenerative Medicine Market for Oncology, by Country/Region, 2022–2031 (USD Million)
Table 30 Global Regenerative Medicine Market for Ophthalmology, by Country/Region, 2022–2031 (USD Million)
Table 31 Global Regenerative Medicine Market for Immunology & Inflammation, by Country/Region, 2022–2031 (USD Million)
Table 32 Global Regenerative Medicine Market for Neurology, by Country/Region, 2022–2031 (USD Million)
Table 33 Global Regenerative Medicine Market for Dermatology, by Country/Region, 2022–2031 (USD Million)
Table 34 Global Regenerative Medicine Market for Cardiology, by Country/Region, 2022–2031 (USD Million)
Table 35 Global Regenerative Medicine Market for Other Applications, by Country/Region, 2022–2031 (USD Million)
Table 36 Global Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 37 Global Regenerative Medicine Market for Hospitals & Clinics, by Country/Region, 2022-2031 (USD Million)
Table 38 Global Regenerative Medicine Market for Ambulatory Surgical Centers, by Country/Region, 2022-2031 (USD Million)
Table 39 Global Regenerative Medicine Market, by Country/Region, 2022–2031 (USD Million)
Table 40 North America: Regenerative Medicine Market, by Country, 2022–2031 (USD Million)
Table 41 North America: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 42 North America: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 43 North America: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 44 North America: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
Table 45 North America: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 46 U.S.: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 47 U.S.: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 48 U.S.: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 49 U.S.: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
Table 50 U.S.: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 51 Canada: Approved Regenerative Medicine, 2021-2024
Table 52 Canada: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 53 Canada: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 54 Canada: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 55 Canada: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 56 Canada: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 57 Europe: Regenerative Medicine Sector Data, Q2 2024 Vs. Q1 2023
Table 58 Europe: Regenerative Medicine Market, by Country/Region, 2022–2031 (USD Million)
Table 59 Europe: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 60 Europe: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 61 Europe: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 62 Europe: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
Table 63 Europe: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 64 Germany: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 65 Germany: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 66 Germany: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 67 Germany: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 68 Germany: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 69 U.K.: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 70 U.K.: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 71 U.K.: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 72 U.K.: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
Table 73 U.K.: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 74 France: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 75 France: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 76 France: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 77 France: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 78 France: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 79 Switzerland: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 80 Switzerland: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 81 Switzerland: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 82 Switzerland: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 83 Switzerland: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 84 Italy: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 85 Italy: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 86 Italy: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 87 Italy: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
Table 88 Italy: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 89 Spain: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 90 Spain: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 91 Spain: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 92 Spain: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 93 Spain: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 94 Netherlands: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 95 Netherlands: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 96 Netherlands: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 97 Netherlands: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 98 Netherlands: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 99 Sweden: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 100 Sweden: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 101 Sweden: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 102 Sweden: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 103 Sweden: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 104 Rest of Europe: Estimated Number of New Cancer Cases, by Country, 2022 Vs. 2030
Table 105 Rest of Europe: Recent Developments In The Regenerative Medicine Market
Table 106 Rest of Europe: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 107 Rest of Europe: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 108 Rest of Europe: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 109 Rest of Europe: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 110 Rest of Europe: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 111 Asia-Pacific: Regenerative Medicine Sector Data, Q2 2024 Vs. Q1 2023
Table 112 Asia-Pacific: Regenerative Medicine Market, by Country/Region, 2022–2031 (USD Million)
Table 113 Asia-Pacific: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 114 Asia-Pacific: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 115 Asia-Pacific: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 116 Asia-Pacific: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
Table 117 Asia-Pacific: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 118 Japan: Approved Regenerative Medicine
Table 119 Japan: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 120 Japan: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 121 Japan: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 122 Japan: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 123 Japan: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 124 China: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 125 China: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 126 China: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 127 China: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 128 China: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 129 Australia: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 130 Australia: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 131 Australia: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 132 Australia: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 133 Australia: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 134 India: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 135 India: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 136 India: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 137 India: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 138 India: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 139 South Korea: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 140 South Korea: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 141 South Korea: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 142 South Korea: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 143 South Korea: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 144 Rest of Asia-Pacific: Recent Developments in Regenerative Medicine Market, by Country
Table 145 Rest of Asia-Pacific: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 146 Rest of Asia-Pacific: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 147 Rest of Asia-Pacific: Stem Cell Therapy Market, by Type, 2022–2031 (USD Million)
Table 148 Rest of Asia-Pacific: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
Table 149 Rest of Asia-Pacific: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 150 Latin America: Regenerative Medicine Market, by Country/Region, 2022–2031 (USD Million)
Table 151 Latin America: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 152 Latin America: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 153 Latin America: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 154 Latin America: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
Table 155 Latin America: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 156 Brazil: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 157 Brazil: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 158 Brazil: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 159 Brazil: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 160 Brazil: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 161 Mexico: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 162 Mexico: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 163 Mexico: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 164 Mexico: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 165 Mexico: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 166 Rest of Latin America: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 167 Rest of Latin America: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 168 Rest of Latin America: Stem Cell Therapy Market, by Type, 2022–2031 (USD Million)
Table 169 Rest of Latin America: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 170 Rest of Latin America: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 171 Middle East & Africa: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 172 Middle East & Africa: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 173 Middle East & Africa: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 174 Middle East & Africa: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 175 Middle East & Africa: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 176 Recent Developments, by Company, 2021–2024
